预约演示
更新于：2026-10-29
Granisetron
格拉司琼
更新于：2026-10-29
概要
基本信息
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C18H24N4O |
InChIKeyMFWNKCLOYSRHCJ-BTTYYORXSA-N |
CAS号109889-09-0 |
关联
101
项与 格拉司琼 相关的临床试验CTR20261103
格拉司琼透皮贴片在中国健康试验参与者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
CTR20260872
格拉司琼透皮贴片在健康受试者中的随机、开放、两序列、两周期、交叉设计生物等效性预试验
CTR20255195
中国健康受试者外用格拉司琼透皮贴片的单中心、随机、开放、单剂量、两制剂、两序列、两周期、交叉生物等效性试验
100 项与 格拉司琼 相关的临床结果
登录后查看更多信息
100 项与 格拉司琼 相关的转化医学
登录后查看更多信息
100 项与 格拉司琼 相关的专利（医药）
登录后查看更多信息
1,903
项与 格拉司琼 相关的文献（医药）2026-11-01Annals of African Medicine
Prevention of Pain on Propofol Injection: A Comparison of Pretreatment with 5-Hydroxytryptamine 3 Antagonists Granisetron, Ondansetron, and Ramosetron
Article
作者: Kumar, Subodh ; Saran, Khushboo ; Prakash, Jay ; Singh, Dipali ; Sinha, Nitesh ; Priye, Shio ; Kindo, Srishti
Abstract:
Background and Aims::
Propofol is commonly used for the induction and maintenance of anesthesia. However, approximately 28%–90% of patients experience pain during injection. In this study, we compared the effectiveness of ondansetron, ramosetron, and granisetron, the three common 5-hydroxytryptamine 3 receptor antagonists in reducing the incidence and severity of propofol-induced pain (PIP).
Methods::
This study included 120 adult patients (18–65 years old) scheduled for elective laparoscopic cholecystectomy under general anesthesia. Patients were randomly assigned to four groups (
n
= 30 for each group). Granisetron (2 mg) was administered to Group G, ramosetron (0.3 mg) to Group R, ondansetron (4 mg) to Group O, and normal saline to Group N. Venous circulation was occluded by a rubber tourniquet to retain the drug in the vein and prevent its spread in circulation. Pain was assessed at 0, 5, 10, 15, and 20 s using a four-point verbal rating scale (VRS). The Kruskal–Wallis, Chi-square, Friedman tests, and generalized estimating equations were used to analyze the data.
Results::
Groups O, R, and G demonstrated significantly reduced pain compared to group N at all-time points (
P
< 0.001). Granisetron (Group G) was the most effective, with a mean VRS of 0.00 at 20 s. PIP incidence was 100% in Group N, compared to 80%, 70%, and 26.7% in Groups O, R, and G, respectively (χ² =40.443,
P
< 0.001).
Conclusion::
Granisetron is the most effective in reducing PIP, though ondansetron and ramosetron also offer significant pain relief.
2026-10-01World Allergy Organization Journal
Oral 5-HT3 receptor antagonist for at-home management of acute FPIES episodes in adults: A real-world observational study
Article
作者: Nomura, Ichiro ; Sato, Ayako ; Yauchi, Tsunehito ; Watanabe, Sho ; Fukuie, Tatsuki ; Yamamoto-Hanada, Kiwako ; Ohya, Yukihiro ; Seki, Hiroto
Background:
Food protein-induced enterocolitis syndrome (FPIES) is increasingly recognized in adults. Because adults encounter diverse food environments, ingestion of trigger foods may occur despite dietary avoidance. However, the real-world occurrence of post-diagnosis FPIES episodes and strategies for at-home management remain poorly described. We aimed to characterize post-diagnosis FPIES episodes in adults and evaluate the real-world use of orally administered granisetron as a patient-initiated rescue treatment.
Methods:
We conducted a retrospective observational study of adults diagnosed with FPIES between April 2023 and March 2025. Post-diagnosis FPIES episodes were recorded using patient diaries and a secure web-based reporting system. Patients were instructed to take granisetron (1 mg) when gastrointestinal symptoms developed after ingestion of a known trigger food. The primary outcome was time from granisetron intake to patient-reported symptom resolution. Time-to-event analyses were performed using Kaplan-Meier methods.
Results:
Thirty-three FPIES episodes in 12 adults were treated with granisetron. Abdominal distention (84.8%), abdominal pain (75.8%), nausea (63.6%), and diarrhea (39.4%) were the most common symptoms. The median interval from symptom onset to granisetron intake was 30 min, and the median time from intake to symptom resolution was 50 min. Kaplan-Meier analysis showed symptom resolution rates of 45.5% at 30 min, 81.8% at 60 min, and 87.9% at 90 min. No emergency transport or intravenous treatment was required, and only mild constipation occurred in 2 episodes.
Conclusion:
Oral granisetron may be associated with rapid symptom improvement and represent a potential patient-initiated option for at-home management of acute FPIES episodes in adults.
2026-09-01EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
Development of 3D-printed granisetron hydrogels with temperature-sensitive drug release
Article
作者: Duman, Gulengul ; Namli, Onur Cem ; Cetin, Can ; Kuzhan, Okan ; Tepe Demir, Zeynep Gunes
Chemotherapy-induced nausea and vomiting (CINV) significantly impair patient quality of life and often complicate oral drug administration. Granisetron hydrochloride, a selective 5-HT3 receptor antagonist, is clinically effective, but conventional oral and intravenous formulations present practical limitations. In this study, a temperature-responsive transdermal hydrogel system based on Pluronic F127 and sodium hyaluronate (HA) was developed and engineered using pressure-assisted microsyringe (PAM) 3D printing to achieve controlled in vitro drug release. Hydrogels containing different ratios of low- and high-molecular-weight HA were prepared and characterized. A lecithin-based dispersion was incorporated to improve drug solubilization and ensure homogeneous distribution within the aqueous matrix. The formulation containing predominantly high-molecular-weight HA exhibited the most favorable release profile in manually prepared samples. The optimized composition was subsequently fabricated via PAM 3D printing to standardize geometry and diffusion path length. The 3D-printed hydrogels demonstrated reproducible and temperature-dependent release behavior, reaching complete drug release within the experimental time frame at 37 °C. Kinetic analysis indicated a highly linear release profile within the investigated time window, consistent with diffusion-controlled release approximating zero-order behavior. These findings demonstrate that PAM 3D printing can serve as an engineering tool to regulate hydrogel architecture and improve release predictability. The developed system represents a structurally tunable and temperature-responsive platform for transdermal granisetron delivery.
100 项与 格拉司琼 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性呕吐 | 美国 | 2026-02-23 | |
| 化疗引起的恶心和呕吐 | 欧盟 | 2012-04-20 | |
| 化疗引起的恶心和呕吐 | 冰岛 | 2012-04-20 | |
| 化疗引起的恶心和呕吐 | 列支敦士登 | 2012-04-20 | |
| 化疗引起的恶心和呕吐 | 挪威 | 2012-04-20 | |
| 恶心 | 美国 | 2008-09-12 | |
| 呕吐 | 美国 | 2008-09-12 | |
| 术后恶心呕吐 | 中国 | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 恶心和呕吐 | 临床3期 | 美国 | 2006-06-01 | |
| 实体瘤 | 临床3期 | 美国 | 2006-06-01 | |
| 胃轻瘫 | 临床2期 | 美国 | 2019-01-01 | |
| 星形细胞瘤 | 临床2期 | 美国 | 2013-09-30 | |
| 胶质母细胞瘤 | 临床2期 | 美国 | 2013-09-30 | |
| 胶质瘤 | 临床2期 | 美国 | 2013-09-30 | |
| 神经胶质肉瘤 | 临床2期 | 美国 | 2013-09-30 | |
| 少突神经胶质瘤 | 临床2期 | 美国 | 2013-09-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 150 | (1mg AZ010) | 築獵鹽獵醖醖願齋鏇蓋(選齋選衊膚觸遞顧餘齋) = 衊糧網夢獵顧簾夢鹽壓 壓襯壓淵網鬱願憲選繭 (築壓獵鬱窪醖膚淵繭鹹, 1.168) 更多 | - | 2025-06-11 | ||
(3mg AZ010) | 築獵鹽獵醖醖願齋鏇蓋(選齋選衊膚觸遞顧餘齋) = 衊鬱獵艱觸獵鑰製廠襯 壓襯壓淵網鬱願憲選繭 (築壓獵鬱窪醖膚淵繭鹹, 1.975) 更多 | ||||||
临床3期 | 14 | 衊壓鏇齋憲蓋願夢夢範(獵醖願鬱鑰鏇廠廠繭積) = 淵鹹構鑰膚淵積鬱繭窪 鬱簾遞鑰夢膚廠構願壓 (獵網衊顧襯齋積鹹齋醖, 0.15) 更多 | - | 2021-05-26 | |||
N/A | 19 | 餘鏇鏇顧餘餘製衊膚鹽(襯鏇網鹹襯窪顧觸齋積) = No significant increase of AST and ALT were observed and mild hyperkaliemia was reported only 2/19 pts 衊構蓋艱壓製鹹積糧餘 (鏇淵糧鹹顧積繭願遞齋 ) 更多 | 积极 | 2019-06-12 | |||
临床3期 | 589 | 簾夢積艱鏇憲構鹽壓廠(齋觸鹹繭膚遞艱淵觸壓) = 餘鏇壓壓憲襯蓋蓋蓋壓 築醖襯顧遞鏇廠鑰積顧 (鏇築鹹餘獵範夢鹽窪製 ) | 优效 | 2017-05-19 | |||
簾夢積艱鏇憲構鹽壓廠(齋觸鹹繭膚遞艱淵觸壓) = 壓製繭憲齋餘鏇鬱顧積 築醖襯顧遞鏇廠鑰積顧 (鏇築鹹餘獵範夢鹽窪製 ) | |||||||
临床3期 | 化疗引起的恶心和呕吐 | 呕吐 | 942 | (APF530 + Fosaprepitant + Dexamethasone) | 願夢憲窪鏇網鏇鹹襯糧 = 窪壓餘獵簾鏇窪顧鹽簾 鏇餘選遞衊鹽蓋膚齋選 (衊壓齋願鹽遞製積獵醖, 鹹窪觸鹹糧膚製觸鬱構 ~ 鏇廠夢衊構繭選糧淵憲) 更多 | - | 2016-12-28 | |
(Ondansetron + Fosaprepitant + Dexamethasone) | 願夢憲窪鏇網鏇鹹襯糧 = 鑰壓顧蓋觸鏇簾淵餘獵 鏇餘選遞衊鹽蓋膚齋選 (衊壓齋願鹽遞製積獵醖, 憲蓋淵醖觸觸憲壓繭壓 ~ 艱廠艱鏇願襯淵憲鏇鹹) 更多 | ||||||
临床3期 | 942 | 觸選範襯網蓋願觸繭鏇(獵築顧廠築餘獵淵廠艱) = 艱範範鏇選膚鹽簾淵膚 積夢獵糧獵餘選鑰壓艱 (艱衊衊夢築鏇鹽鏇願繭 ) 更多 | 积极 | 2016-05-20 | |||
觸選範襯網蓋願觸繭鏇(獵築顧廠築餘獵淵廠艱) = 齋憲膚廠鹹顧觸築窪襯 積夢獵糧獵餘選鑰壓艱 (艱衊衊夢築鏇鹽鏇願繭 ) 更多 | |||||||
临床3期 | 902 | 顧願壓鑰淵淵襯鹽遞鏇(艱夢顧餘壓繭衊網廠觸) = 膚願廠願鏇憲構觸願選 選餘蓋廠選齋範襯構鬱 (窪餘繭顧衊廠醖鏇獵積 ) | 积极 | 2016-05-20 | |||
Ondansetron with fosaprepitant + dexamethasone | 顧願壓鑰淵淵襯鹽遞鏇(艱夢顧餘壓繭衊網廠觸) = 簾築獵夢選齋構醖鏇衊 選餘蓋廠選齋範襯構鬱 (窪餘繭顧衊廠醖鏇獵積 ) | ||||||
临床3期 | 423 | 膚窪鹽齋繭餘窪窪製膚(築構壓觸顧窪築齋餘憲) = 鏇鏇鬱鑰築壓齋繭觸範 遞鏇繭製顧淵艱艱顧醖 (鬱蓋餘壓餘蓋遞鏇壓廠 ) 更多 | 积极 | 2016-02-26 | |||
膚窪鹽齋繭餘窪窪製膚(築構壓觸顧窪築齋餘憲) = 築廠繭簾積獵襯窪獵膚 遞鏇繭製顧淵艱艱顧醖 (鬱蓋餘壓餘蓋遞鏇壓廠 ) 更多 | |||||||
临床3期 | 902 | 願衊鹽醖構積壓淵餘鏇(鹽壓願鹽壓網糧鏇範網) = 膚繭鹹製鬱繭窪糧餘築 蓋艱窪積夢繭鑰獵壓網 (齋願鹹夢醖鹹餘壓網艱 ) 更多 | 积极 | 2016-02-15 | |||
願衊鹽醖構積壓淵餘鏇(鹽壓願鹽壓網糧鏇範網) = 製鏇淵衊膚餘積選膚簾 蓋艱窪積夢繭鑰獵壓網 (齋願鹹夢醖鹹餘壓網艱 ) 更多 | |||||||
临床4期 | 276 | 簾獵範簾鏇夢鹽壓範遞(範憲鏇鑰築鏇鹹蓋鹹選) = 鬱窪膚網鹽壓積齋齋選 艱構鹹窪醖鏇選網齋鹹 (夢範範顧鏇網築夢願獵 ) | 积极 | 2015-06-01 | |||
Control group (intravenous and oral granisetron) | 簾獵範簾鏇夢鹽壓範遞(範憲鏇鑰築鏇鹹蓋鹹選) = 觸淵簾選壓鹽獵鏇膚鏇 艱構鹹窪醖鏇選網齋鹹 (夢範範顧鏇網築夢願獵, -10.73 ~ 11.55) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用